IRON STATUS AND RISK OF CHD AND COLON CANCER

描述：(改编自《调查员摘要》)调查员 建议前瞻性地检查铁状况(摄入量、 身体储存和血色素沉着症的遗传易感性)和风险 三个大队列中的心肌梗死(MI)和结直肠癌。 铁的摄入量通过半定量食物频率问卷进行评估。 (SFFQ)于1980年在护士健康研究(NHS，n=121,700名妇女)和 1986年在NHS和卫生专业人员后续研究(HPFS， N=51,529名男性)。血液样本都是在这两个队列中采集的： 1989-90年的NHS(n=32,825名妇女)和1993-94年的HPFS(n=18,000名男子)。 此外，还从参与调查的人那里收集了样本 1982年医生健康研究(PHS，n=14,916名男性)。这些男人和女人 最初没有心血管疾病和癌症，并一直在跟踪 前瞻性地用于心血管疾病和癌症的发生。这个 研究人员计划在嵌套病例对照设计中对样本进行化验， 对于体内铁储存的生物标志物(铁，总铁结合力， 铁蛋白)和遗传性血色素沉着症的遗传标记 铁超载(C282Y，人类白细胞抗原H基因错义突变)。这个 铁-CHD/癌症假说已得到实验室和动物的支持 研究，但来自较小、不太全面的流行病学研究的结果 是不一致的。他们建议评估个人与 摄入量、生物标记物水平和基因型与心肌梗死和结直肠癌的风险 癌症，以及它们的综合作用。此外，他们将评估其他 可能解释或改变这种联系的饮食和生活方式因素 铁与心肌梗死/结直肠癌之间的关系。正在进行的三个队列将 提供高收益的后续参与和高质量的终端 除了关于重要变量的信息之外的验证(例如， 吸烟、维生素补充剂的使用、饮食因素)。 这些分析将利用现有的这些血库 特征良好的队列，以及部分血浆铁蛋白测量 (NHS和PHS)通过其他来源获得资金。调查人员表示 因此，这个应用程序提供了一个聚焦良好、高效的 经济高效、全面的方法来评估假设的BUT 铁作为未来心血管疾病的危险因素的作用未经证实 癌症。

DESCRIPTION: (Adapted from Investigator's Abstract) The investigators propose to examine prospectively the relation between iron status (intake, body stores, and genetic susceptibility for hemochromatosis) and risk of myocardial infarction (MI) and colorectal cancer in three large cohorts. Iron intake was assessed by semiquantitative food frequency questionnaire (SFFQ) in 1980 in the Nurses' Health Study (NHS, n=121,700 women) and in 1986 in the NHS and in the Health Professionals Follow-up Study (HPFS, n=51,529 men). Blood samples were collected in both of these cohorts: from the NHS in 1989-90 (n=32,825 women), and the HPFS in 1993-94 (n=18,000 men). In addition, samples also were collected from participants in the Physicians' Health Study in 1982 (PHS, n=14,916 men). These men and women initially free of cardiovascular disease and cancer and have been followed prospectively for the occurrence of cardiovascular disease and cancer. The investigators plan to assay the samples, in a nested case-control design, for biomarkers of body iron stores (iron, total iron binding capacity, ferritin) and genetic marker of hemochromatosis, an inherited disease of iron overload (C282Y, a missense mutation in HLA-H gene). The iron-CHD/cancer hypotheses have been supported by laboratory and animal studies, but findings from small, less comprehensive epidemiologic studies are inconsistent. They propose to evaluate the individual associations of intake, biomarker levels, and genotype with risk of MI and colorectal cancer, as well as the combined effects. Further, they will evaluate other dietary and lifestyle factors that may account for or modify the association between iron and MI/colorectal cancer. The ongoing three cohorts will provide high yield follow-up participation and high quality end-point verification in addition to information on important variables (e.g., smoking, vitamin supplement use, dietary factors) for the proposed study. These analyses will take advantage of existing blood banks of these well-characterized cohorts, and part of the plasma ferritin measurements (the NHS and PHS) are funded through other sources. The investigators state that hence, this application provides a well-focused, efficient cost-effective, and comprehensive approach to evaluate the hypothesized but unproven role of iron as a risk factor for future cardiovascular disease and cancer.